Phase 2 × Completed × Leukemia, Lymphocytic, Chronic, B-Cell × Clear all Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia
Phase 2 Completed
42 enrolled
MERIT
Phase 2 Completed
35 enrolled 7 charts
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Phase 2 Completed
87 enrolled 19 charts
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Completed
15 enrolled 9 charts
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
Phase 2 Completed
96 enrolled
Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825)
Phase 2 Completed
17 enrolled 5 charts
Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL
Phase 2 Completed
48 enrolled 12 charts
Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
Phase 2 Completed
45 enrolled 12 charts
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Phase 2 Completed
41 enrolled
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
Phase 2 Completed
34 enrolled 14 charts
ICLL07GAI
Phase 2 Completed
135 enrolled
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 2 Completed
20 enrolled
A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL
Phase 2 Completed
37 enrolled
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
23 enrolled 9 charts
HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide
Phase 2 Completed
80 enrolled 56 charts
CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7
Phase 2 Completed
52 enrolled
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Phase 2 Completed
15 enrolled 15 charts
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT
Phase 2 Completed
78 enrolled 16 charts
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease
Phase 2 Completed
135 enrolled 19 charts
Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Phase 2 Completed
61 enrolled 10 charts
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Phase 2 Completed
19 enrolled
Captivate
Phase 2 Completed
323 enrolled 33 charts
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Completed
91 enrolled 14 charts
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Phase 2 Completed
39 enrolled 8 charts
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 2 Completed
44 enrolled 7 charts
Phase II Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
30 enrolled 12 charts
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
21 enrolled 12 charts
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
35 enrolled 11 charts
Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation
Phase 2 Completed
37 enrolled 12 charts
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Phase 2 Completed
65 enrolled 21 charts
Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma
Phase 2 Completed
60 enrolled
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
COVID-19 VAX Booster Dosing in Patients With Hematologic Malignancies
Phase 2 Completed
119 enrolled 11 charts
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Phase 2 Completed
32 enrolled 16 charts
Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
Phase 2 Completed
76 enrolled 10 charts
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Phase 2 Completed
23 enrolled 10 charts
Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma
Phase 2 Completed
6 enrolled 10 charts
Rituximab, Carmustine; Cytarabine, Etoposide, & Melphalan; Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Phase 2 Completed
68 enrolled
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Phase 2 Completed
35 enrolled
Allo HSCT Using RIC for Hematological Diseases
Phase 2 Completed
156 enrolled
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
Phase 2 Completed
127 enrolled 20 charts
Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Completed
44 enrolled
Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
14 enrolled 9 charts
A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
7 enrolled
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Phase 2 Completed
116 enrolled 11 charts
Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL
Phase 2 Completed
102 enrolled 11 charts
Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL/SLL
Phase 2 Completed
36 enrolled 11 charts
Theophylline in Treating Patients With In Situ, Stage I, or Stage II Chronic Lymphocytic Leukemia
Phase 2 Completed